Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Peptic Ulcer

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 95 articles:
HTML format
Text format



Single Articles


    April 2017
  1. SUGIMOTO M, Ban H, Hira D, Kamiya T, et al
    Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan.
    Aliment Pharmacol Ther. 2017;45:1009-1010.
    PubMed     Text format    


    March 2017
  2. TALEBI BEZMIN ABADI A
    Letter: more studies are needed to elucidate any association between Helicobacter pylori infection and Barrett's metaplasia.
    Aliment Pharmacol Ther. 2017;45:764-765.
    PubMed     Text format    


    February 2017
  3. SHAW J, Bajaj JS
    Editorial: should the inappropriate use of proton pump inhibitors be a quality assurance issue in cirrhotic patients?
    Aliment Pharmacol Ther. 2017;45:476-477.
    PubMed     Text format    


  4. CHEN PY, Wu MS, Liou JM
    Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:573.
    PubMed     Text format    


  5. ZAMANI M, Shokri-Shirvani J, Zamani V
    Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2017;45:572-573.
    PubMed     Text format    


  6. AHN JS, Sinn DH, Son HJ, Gwak GY, et al
    Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply.
    Aliment Pharmacol Ther. 2017;45:577-578.
    PubMed     Text format    


  7. KOUNTOURAS J, Polyzos SA, Kapetanakis N, Katsinelos P, et al
    Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia.
    Aliment Pharmacol Ther. 2017;45:576-577.
    PubMed     Text format    


    January 2017
  8. SCHIAVON LL, Silva TE, Fischer J, Narciso-Schiavon JL, et al
    Letter: proton pump inhibitors and prognosis of cirrhosis - searching for the balance point.
    Aliment Pharmacol Ther. 2017;45:378-379.
    PubMed     Text format    


    November 2016
  9. MIWA H, Uedo N, Watari J, Mori Y, et al
    Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
    Aliment Pharmacol Ther. 2016 Nov 27. doi: 10.1111/apt.13876.
    PubMed     Text format     Abstract available


  10. SONNENBERG A, Turner KO, Spechler SJ, Genta RM, et al
    The influence of Helicobacter pylori on the ethnic distribution of Barrett's metaplasia.
    Aliment Pharmacol Ther. 2016 Nov 9. doi: 10.1111/apt.13854.
    PubMed     Text format     Abstract available


    October 2016
  11. COLE HL, Pennycook S, Hayes PC
    The impact of proton pump inhibitor therapy on patients with liver disease.
    Aliment Pharmacol Ther. 2016 Oct 23. doi: 10.1111/apt.13827.
    PubMed     Text format     Abstract available


  12. SAVARINO E, Girardin G, Della Coletta M, Ottonello A, et al
    Letter: proton pump inhibitor-responsive oesophageal eosinophilia - more than just gastro-oesophageal reflux disease. Authors' reply.
    Aliment Pharmacol Ther. 2016;44:912-3.
    PubMed     Text format    


  13. MOLINA-INFANTE J, Katzka DA, Spechler SJ
    Letter: proton pump inhibitor-responsive oesophageal eosinophilia - more than just gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2016;44:911-2.
    PubMed     Text format    


    September 2016
  14. MARTIN FC, Chenevix-Trench G, Yeomans ND
    Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors.
    Aliment Pharmacol Ther. 2016 Sep 15. doi: 10.1111/apt.13800.
    PubMed     Text format     Abstract available


  15. POINTER SD, Rickstrew J, Slaughter JC, Vaezi MF, et al
    Dietary carbohydrate intake, insulin resistance and gastro-oesophageal reflux disease: a pilot study in European- and African-American obese women.
    Aliment Pharmacol Ther. 2016 Sep 1. doi: 10.1111/apt.13784.
    PubMed     Text format     Abstract available


    August 2016
  16. PATEL A, Wang D, Sainani N, Sayuk GS, et al
    Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2016 Aug 24. doi: 10.1111/apt.13777.
    PubMed     Text format     Abstract available


  17. MALMI H, Kautiainen H, Virta LJ, Farkkila MA, et al
    Letter: risk factor and mortality of peptic ulcer disease - authors' reply.
    Aliment Pharmacol Ther. 2016;44:425.
    PubMed     Text format    


  18. ZHANG XY, Mo HY, Huang Y
    Letter: risk factor and mortality of peptic ulcer disease.
    Aliment Pharmacol Ther. 2016;44:424-5.
    PubMed     Text format    


    July 2016
  19. KAGAWA T, Iwamuro M, Ishikawa S, Ishida M, et al
    Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
    Aliment Pharmacol Ther. 2016 Jul 28. doi: 10.1111/apt.13747.
    PubMed     Text format     Abstract available


  20. SAVARINO EV, Tolone S, Bartolo O, de Cassan C, et al
    The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon.
    Aliment Pharmacol Ther. 2016 Jul 4. doi: 10.1111/apt.13718.
    PubMed     Text format     Abstract available


  21. BYTZER P, Reimer C
    Letter: add-on alginate therapy for reflux patients with inadequate response to a once daily proton pump inhibitor - more questions than answers. Authors' reply.
    Aliment Pharmacol Ther. 2016;44:208.
    PubMed     Text format    


  22. CHEN PZ, Wang CC
    Letter: add-on alginate therapy for reflux patients with inadequate response to a once daily proton pump inhibitor - more questions than answers.
    Aliment Pharmacol Ther. 2016;44:207.
    PubMed     Text format    


    June 2016
  23. CHEN PY, Wu MS, Chen CY, Bair MJ, et al
    Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2016 Jun 30. doi: 10.1111/apt.13712.
    PubMed     Text format     Abstract available


  24. THUNG I, Crowe SE, Valasek MA
    Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. Authors' reply.
    Aliment Pharmacol Ther. 2016;43:1249-50.
    PubMed     Text format    


  25. SHOKRI-SHIRVANI J, Zamani V, Zamani M
    Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions.
    Aliment Pharmacol Ther. 2016;43:1249.
    PubMed     Text format    


  26. MOLINA-INFANTE J, Lucendo AJ, Gisbert JP
    Letter: Helicobacter pylori infection and eosinophilic oesophagitis - causal or casual inverse association?
    Aliment Pharmacol Ther. 2016;43:1244.
    PubMed     Text format    


    May 2016
  27. MALMI H, Kautiainen H, Virta LJ, Farkkila MA, et al
    Increased short- and long-term mortality in 8146 hospitalised peptic ulcer patients.
    Aliment Pharmacol Ther. 2016 May 30. doi: 10.1111/apt.13682.
    PubMed     Text format     Abstract available


  28. HAASTRUP PF, Paulsen MS, Christensen RD, Sondergaard J, et al
    Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
    Aliment Pharmacol Ther. 2016 May 3. doi: 10.1111/apt.13649.
    PubMed     Text format     Abstract available


  29. WALKER AW, Flint HJ
    Editorial: further evidence that proton pump inhibitors may impact on the gut microbiota.
    Aliment Pharmacol Ther. 2016;43:1104-5.
    PubMed     Text format    


  30. REIMER C, Bytzer P
    Editorial: alginates for inadequate response to a proton pump inhibitor in gastro-oesophageal reflux disease - authors' reply.
    Aliment Pharmacol Ther. 2016;43:1104.
    PubMed     Text format    


  31. VAKIL N
    Editorial: alginates for inadequate response to a proton pump inhibitor in gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2016;43:1103.
    PubMed     Text format    


    April 2016
  32. HESS MW, de Baaij JH, Broekman M, Bisseling TM, et al
    Inulin significantly improves serum magnesium levels in proton pump inhibitor-induced hypomagnesaemia.
    Aliment Pharmacol Ther. 2016 Apr 18. doi: 10.1111/apt.13619.
    PubMed     Text format     Abstract available


  33. KHAN F, Maradey-Romero C, Ganocy S, Frazier R, et al
    Utilisation of surgical fundoplication for patients with gastro-oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013.
    Aliment Pharmacol Ther. 2016 Apr 6. doi: 10.1111/apt.13611.
    PubMed     Text format     Abstract available


  34. LIOU JM, Chen MJ, Wu MS
    Letter: could sequential therapy extended to 14 days replace prolonged triple regimens for Helicobacter pylori treatment? Authors' reply.
    Aliment Pharmacol Ther. 2016;43:845-6.
    PubMed     Text format    


  35. LOSURDO G, Iannone A, Giorgio F, Principi M, et al
    Letter: could sequential therapy extended to 14 days replace prolonged triple regimens for Helicobacter pylori treatment?
    Aliment Pharmacol Ther. 2016;43:844-5.
    PubMed     Text format    


    March 2016
  36. CAMUS M, Jensen DM, Kovacs TO, Jensen ME, et al
    Independent risk factors of 30-day outcomes in 1264 patients with peptic ulcer bleeding in the USA: large ulcers do worse.
    Aliment Pharmacol Ther. 2016 Mar 22. doi: 10.1111/apt.13591.
    PubMed     Text format     Abstract available


  37. KAGAMI T, Sahara S, Ichikawa H, Uotani T, et al
    Potent acid inhibition by vonoprazan in comparison with esomeprazole with reference to CYP2C19 genotype.
    Aliment Pharmacol Ther. 2016 Mar 18. doi: 10.1111/apt.13588.
    PubMed     Text format     Abstract available


  38. VERHAEGH BP, de Vries F, Masclee AA, Keshavarzian A, et al
    High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors.
    Aliment Pharmacol Ther. 2016 Mar 9. doi: 10.1111/apt.13583.
    PubMed     Text format     Abstract available


  39. PHILPOTT H, Nandurkar S, Royce SG, Thien F, et al
    A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic oesophagitis.
    Aliment Pharmacol Ther. 2016 Mar 4. doi: 10.1111/apt.13576.
    PubMed     Text format     Abstract available


  40. KUIPERS EJ
    Editorial: proton pump inhibitors, Helicobacter pylori and gastric cancer - the need for long-term follow-up.
    Aliment Pharmacol Ther. 2016;43:647-8.
    PubMed     Text format    


  41. EZEKWUDO D, Tobi M
    Letter: long-term use of proton pump inhibitors and risk of neuroendocrine tumours.
    Aliment Pharmacol Ther. 2016;43:749.
    PubMed     Text format    


  42. DEN HOLLANDER WJ, Sonnenschein-van der Voort AM, Holster IL, de Jongste JC, et al
    Helicobacter pylori in children with asthmatic conditions at school age, and their mothers.
    Aliment Pharmacol Ther. 2016 Mar 1. doi: 10.1111/apt.13572.
    PubMed     Text format     Abstract available


    February 2016
  43. CLOONEY AG, Bernstein CN, Leslie WD, Vagianos K, et al
    A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors.
    Aliment Pharmacol Ther. 2016 Feb 29. doi: 10.1111/apt.13568.
    PubMed     Text format     Abstract available


  44. VON ARNIM U, Wex T, Link A, Messerschmidt M, et al
    Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis.
    Aliment Pharmacol Ther. 2016 Feb 22. doi: 10.1111/apt.13560.
    PubMed     Text format     Abstract available


  45. REIMER C, Lodrup AB, Smith G, Wilkinson J, et al
    Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor.
    Aliment Pharmacol Ther. 2016 Feb 22. doi: 10.1111/apt.13567.
    PubMed     Text format     Abstract available


  46. LEOW AH, Lim YY, Liew WC, Goh KL, et al
    Time trends in upper gastrointestinal diseases and Helicobacter pylori infection in a multiracial Asian population - a 20-year experience over three time periods.
    Aliment Pharmacol Ther. 2016 Feb 5. doi: 10.1111/apt.13550.
    PubMed     Text format     Abstract available


    January 2016
  47. INABA T, Iwamuro M, Toyokawa T, Okada H, et al
    Letter: promising results of Helicobacter pylori eradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy.
    Aliment Pharmacol Ther. 2016;43:179-80.
    PubMed     Text format    


    December 2015
  48. THUNG I, Aramin H, Vavinskaya V, Gupta S, et al
    Review article: the global emergence of Helicobacter pylori antibiotic resistance.
    Aliment Pharmacol Ther. 2015 Dec 23. doi: 10.1111/apt.13497.
    PubMed     Text format     Abstract available


  49. LIOU JM, Chen CC, Lee YC, Chang CY, et al
    Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2015 Dec 15. doi: 10.1111/apt.13495.
    PubMed     Text format     Abstract available


  50. GOMEZ-TORRIJOS E, Garcia-Rodriguez R, Castro-Jimenez A, Rodriguez-Sanchez J, et al
    The Efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia.
    Aliment Pharmacol Ther. 2015 Dec 10. doi: 10.1111/apt.13496.
    PubMed     Text format     Abstract available


    November 2015
  51. ROBERTS SE, Morrison-Rees S, Samuel DG, Thorne K, et al
    Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe.
    Aliment Pharmacol Ther. 2015 Nov 23. doi: 10.1111/apt.13474.
    PubMed     Text format     Abstract available


  52. ASHIDA K, Sakurai Y, Hori T, Kudou K, et al
    Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
    Aliment Pharmacol Ther. 2015 Nov 11. doi: 10.1111/apt.13461.
    PubMed     Text format     Abstract available


  53. SCHNEIDER JL, Kolitsopoulos F, Corley DA
    Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors.
    Aliment Pharmacol Ther. 2015 Nov 6. doi: 10.1111/apt.13450.
    PubMed     Text format     Abstract available


    September 2015
  54. TURNER KO, Genta RM, Sonnenberg A
    Oesophageal signet ring cell carcinoma as complication of gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2015 Sep 8. doi: 10.1111/apt.13395.
    PubMed     Text format     Abstract available


  55. SHAH SL, Lacy BE, DiBaise JK, Vela MF, et al
    The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy.
    Aliment Pharmacol Ther. 2015 Sep 8. doi: 10.1111/apt.13394.
    PubMed     Text format     Abstract available


    August 2015
  56. DING Z, Zhao S, Gong S, Li Z, et al
    Prevalence and risk factors of Helicobacter pylori infection in asymptomatic Chinese children: a prospective, cross-sectional, population-based study.
    Aliment Pharmacol Ther. 2015 Aug 14. doi: 10.1111/apt.13364.
    PubMed     Text format     Abstract available


  57. MARCUS EA, Sachs G, Scott DR
    Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics.
    Aliment Pharmacol Ther. 2015 Aug 4. doi: 10.1111/apt.13346.
    PubMed     Text format     Abstract available


  58. WALDUM HL, Hauso O, Fossmark R
    Letter: proton pump inhibitors, hypergastrinaemia and the risk of gastric neoplasia.
    Aliment Pharmacol Ther. 2015;42:389.
    PubMed     Text format    


  59. MOAWAD FJ
    Editorial: proton pump inhibitor-responsive oesophageal eosinophilia - two different phenotypes? - Author's reply.
    Aliment Pharmacol Ther. 2015;42:487-8.
    PubMed     Text format    


  60. MOLINA-INFANTE J, Katzka DA
    Editorial: proton pump inhibitor-responsive oesophageal eosinophilia - two different phenotypes?
    Aliment Pharmacol Ther. 2015;42:485-7.
    PubMed     Text format    


    July 2015
  61. SUN J, Yang C, Zhao H, Zheng P, et al
    Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
    Aliment Pharmacol Ther. 2015 Jul 31. doi: 10.1111/apt.13334.
    PubMed     Text format     Abstract available


  62. ASHIDA K, Sakurai Y, Nishimura A, Kudou K, et al
    Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
    Aliment Pharmacol Ther. 2015 Jul 22. doi: 10.1111/apt.13331.
    PubMed     Text format     Abstract available


  63. SAKURAI Y, Mori Y, Okamoto H, Nishimura A, et al
    Randomised clinical trial: acid-inhibitory effect of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study.
    Aliment Pharmacol Ther. 2015 Jul 21. doi: 10.1111/apt.13325.
    PubMed     Text format     Abstract available


  64. LUNDELL L, Vieth M, Gibson F, Nagy P, et al
    Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
    Aliment Pharmacol Ther. 2015 Jul 16. doi: 10.1111/apt.13324.
    PubMed     Text format     Abstract available


  65. KAPPELLE WF, Bredenoord AJ, Conchillo JM, Ruurda JP, et al
    Electrical stimulation therapy of the lower oesophageal sphincter for refractory gastro-oesophageal reflux disease - interim results of an international multicentre trial.
    Aliment Pharmacol Ther. 2015 Jul 8. doi: 10.1111/apt.13306.
    PubMed     Text format     Abstract available


  66. ESTBORN L, Joelson S
    Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies.
    Aliment Pharmacol Ther. 2015 Jul 3. doi: 10.1111/apt.13304.
    PubMed     Text format     Abstract available


    June 2015
  67. TSENG CL, Chen YT, Huang CJ, Luo JC, et al
    Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study.
    Aliment Pharmacol Ther. 2015 Jun 22. doi: 10.1111/apt.13298.
    PubMed     Text format     Abstract available


  68. SUGIMOTO M, Sahara S, Ichikawa H, Kagami T, et al
    High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.
    Aliment Pharmacol Ther. 2015 Jun 15. doi: 10.1111/apt.13280.
    PubMed     Text format     Abstract available


  69. DULTZ G, Piiper A, Zeuzem S, Kronenberger B, et al
    Letter: proton pump inhibitor treatment and increased mortality in cirrhotic patients - authors' reply.
    Aliment Pharmacol Ther. 2015;41:1225.
    PubMed     Text format    


  70. SCHWORER H, Sossalla S, Schillinger W
    Letter: proton pump inhibitor treatment and increased mortality in cirrhotic patients.
    Aliment Pharmacol Ther. 2015;41:1224.
    PubMed     Text format    


    May 2015
  71. TAHA AS, McCloskey C, Craigen T, Simpson A, et al
    Occult vs. overt upper gastrointestinal bleeding - inverse relationship and the use of mucosal damaging and protective drugs.
    Aliment Pharmacol Ther. 2015 May 24. doi: 10.1111/apt.13265.
    PubMed     Text format     Abstract available


  72. HARB AH, Chalhoub JM, Abou Mrad R, Sharara AI, et al
    Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2015 May 24. doi: 10.1111/apt.13259.
    PubMed     Text format     Abstract available


  73. MOAWAD FJ, Wells JM, Johnson RL, Reinhardt BJ, et al
    Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 2015 May 24. doi: 10.1111/apt.13258.
    PubMed     Text format     Abstract available


  74. IWAKURA N, Fujiwara Y, Arakawa T
    Editorial: is eosinophilic oesophagitis different to proton pump inhibitor-responsive oesophageal eosinophilia? Authors' reply.
    Aliment Pharmacol Ther. 2015;41:1024-5.
    PubMed     Text format    


  75. MOLINA-INFANTE J, Moawad FJ, van Rhijn BD
    Editorial: is eosinophilic oesophagitis different to proton pump inhibitor-responsive oesophageal eosinophilia?
    Aliment Pharmacol Ther. 2015;41:1023-4.
    PubMed     Text format    


    April 2015
  76. SZAJEWSKA H, Horvath A, Kolodziej M
    Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2015 Apr 21. doi: 10.1111/apt.13214.
    PubMed     Text format     Abstract available


  77. WANG YP, Liu CJ, Chen TJ, Lin YT, et al
    Proton pump inhibitor use significantly increases the risk of cryptogenic liver abscess: a population-based study.
    Aliment Pharmacol Ther. 2015 Apr 13. doi: 10.1111/apt.13203.
    PubMed     Text format     Abstract available


  78. ATTWOOD SE, Ell C, Galmiche JP, Fiocca R, et al
    Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.
    Aliment Pharmacol Ther. 2015 Apr 10. doi: 10.1111/apt.13194.
    PubMed     Text format     Abstract available


  79. DULTZ G, Piiper A, Zeuzem S, Kronenberger B, et al
    Letter: proton pump inhibitors - severity of liver disease and mortality in patients with cirrhosis - authors' reply.
    Aliment Pharmacol Ther. 2015;41:706.
    PubMed     Text format    


  80. LIN S, Dong J
    Letter: proton pump inhibitors - severity of liver disease and mortality in patients with cirrhosis.
    Aliment Pharmacol Ther. 2015;41:704-5.
    PubMed     Text format    


  81. HOLLAND-BILL L, Christiansen CF, Gammelager H, Sorensen HT, et al
    Editorial: chronic liver disease and deaths from peptic ulcer bleeding - authors' reply.
    Aliment Pharmacol Ther. 2015;41:787-8.
    PubMed     Text format    


  82. SIGOUNAS DE, Penman ID
    Editorial: chronic liver disease and deaths from peptic ulcer bleeding.
    Aliment Pharmacol Ther. 2015;41:787.
    PubMed     Text format    


    March 2015
  83. MELINDER C, Udumyan R, Hiyoshi A, Brummer RJ, et al
    Decreased stress resilience in young men significantly increases the risk of subsequent peptic ulcer disease - a prospective study of 233 093 men in Sweden.
    Aliment Pharmacol Ther. 2015 Mar 23. doi: 10.1111/apt.13168.
    PubMed     Text format     Abstract available


  84. GENTA RM, Sonnenberg A
    Letter: effect of proton pump inhibitor use on invasive detection of Helicobacter pylori gastritis - authors' reply.
    Aliment Pharmacol Ther. 2015;41:600.
    PubMed     Text format    


  85. BRUMMOND NR, Saito YA, Locke GR 3rd, Larson JJ, et al
    Letter: role of GNbeta3 polymorphisms in oesophageal adenocarcinoma and gastroesophageal reflux disease.
    Aliment Pharmacol Ther. 2015;41:600-1.
    PubMed     Text format    


  86. KILINCALP S, Ustun Y, Akinci H, Coban S, et al
    Letter: effect of proton pump inhibitor use on invasive detection of Helicobacter pylori gastritis.
    Aliment Pharmacol Ther. 2015;41:599.
    PubMed     Text format    


  87. SUTHERLAND D, Stanley AJ
    Editorial: proton pump inhibitors in cirrhosis.
    Aliment Pharmacol Ther. 2015;41:592.
    PubMed     Text format    


  88. MOLINA-INFANTE J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, et al
    Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study.
    Aliment Pharmacol Ther. 2015;41:581-9.
    PubMed     Text format     Abstract available


    February 2015
  89. GISBERT JP, Romano M, Gravina AG, Solis-Munoz P, et al
    Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Aliment Pharmacol Ther. 2015 Feb 23. doi: 10.1111/apt.13128.
    PubMed     Text format     Abstract available


  90. IWAKURA N, Fujiwara Y, Tanaka F, Tanigawa T, et al
    Basophil infiltration in eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia.
    Aliment Pharmacol Ther. 2015 Feb 19. doi: 10.1111/apt.13141.
    PubMed     Text format     Abstract available


  91. SHAHEEN NJ, Adler J, Dedrie S, Johnson D, et al
    Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapy.
    Aliment Pharmacol Ther. 2015 Feb 19. doi: 10.1111/apt.13115.
    PubMed     Text format     Abstract available


    January 2015
  92. HOLLAND-BILL L, Christiansen CF, Gammelager H, Mortensen RN, et al
    Chronic liver disease and 90-day mortality in 21 359 patients following peptic ulcer bleeding - a Nationwide Cohort Study.
    Aliment Pharmacol Ther. 2015 Jan 15. doi: 10.1111/apt.13073.
    PubMed     Text format     Abstract available


    December 2014
  93. DULTZ G, Piiper A, Zeuzem S, Kronenberger B, et al
    Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis.
    Aliment Pharmacol Ther. 2014 Dec 19. doi: 10.1111/apt.13061.
    PubMed     Text format     Abstract available


  94. HOWDEN CW
    PPI vs. teprenone in preventing recurrence of ulcers during low-dose aspirin.
    Aliment Pharmacol Ther. 2014;40.
    PubMed     Text format    


  95. IWAKIRI R, Fujimoto K
    PPI vs. teprenone in preventing recurrence of ulcers during low-dose aspirin - authors' reply.
    Aliment Pharmacol Ther. 2014;40.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Peptic Ulcer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: